APVO News and Press, Aptevo Therapeutics Inc. From 08/09/19

Reports Positive Preliminary Top-Line Safety Data for APVO210 Phase 1 Single Ascending Dose (SAD) Clinical Study Advances APVO210 into Phase 1 Multiple Ascending Dose (MAD) Study Commences Dosing in Cohort 4 of APVO436 Phase 1 AML/MDS Clinical Trial Achieves 32% Increase in ...

SEATTLE, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today the receipt of a $4.3 million milestone payment from Saol International Limited (Saol). This performa...

While there is not much in terms of headline news for Aptevo Therapeutics ( APVO ) as of late, there are many things happening "under the hood" that might warrant investor's attention. Because depending on how things proceed for the company, the profits to be had for investors might be extra...

Completes Dosing in Single Ascending Dose (SAD) Phase 1 Study of APVO210 Receives Approval to Begin APVO210 Multiple Ascending Dose (MAD) Study Preliminary Data Suggest that Single Doses of APVO210 Appear to be Safe and Well Tolerated at Doses Equivalent to IL-10 Doses that Genera...

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...

Expands Options for Patients with Potential for  Reduced Reconstitution Time and Infusion Volume SEATTLE, June 25, 2019 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeuti...

Aptevo Therapeutics (NASDAQ: APVO ): Q1 GAAP EPS of -$0.44 in-line. More news on: Aptevo Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Achieves 73% Increase in First Quarter 2019 Year-Over-Year IXINITY® Net Revenue On Target for Launch of New 3,000 IU IXINITY Assay Mid-2019 Advances Enrollment in APVO436 and APVO210 Phase 1 Clinical Studies; Anticipates Top-Line Preliminary Data Read-outs in the Third a...

Reports 73% Increase in IXINITY Year-Over-Year Quarterly Net Revenue in Q1 2019 Anticipates Launching New IXINITY 3,000 IU Assay Mid-2019 Advances Dosing in Additional Cohorts in APVO436 and APVO210 Clinical Programs On Schedule to File a CTA for ALG.APV-527 in Q4 2019 SEAT...

The following slide deck was published by Aptevo Therapeutics Inc. in conjunction with this Read more ...